Skip to main content
. 2012 Aug 10;18(1):16–25. doi: 10.1016/j.rpor.2012.07.014

Table 2.

Clinical characteristics of HNSCC: comparison between elderly patients and younger age groups (only studies on different primary tumor sites and with >100 patients included in the elderly study group are presented).

Author (year)Ref. Time span N M:F ratio Primary tumor site, % Stage, % Treatment, % Outcome, % New PTs, %
Barzan et al. (1990)5 1981–1984 438 OC vs. OPh vs. HPh vs. Lx vs. others I vs. II vs. III vs. IV S/contraindications for S 5-Year OSa,b
 <70 years 331 8.9:1 13 vs. 26 vs. 13 vs. 38 vs. 10 22 vs. 18 vs. 25 vs. 35 78/9 86 27
 ≥70 years 107 7.9:1 16 vs. 22 vs. 6 vs. 37 vs. 19 29 vs. 20 vs. 21 vs. 31 57/23 83 28
Sarini et al. (2001)6 1974–1983 4610 OC vs. OPh vs. HPh vs. Lx I + II vs. III + IV/N0/M1 ST vs. SN vs. S + RT vs. RT + ChT vs. ChT 5-Year OSc
 <75 years 4337 25:1 33.8 vs. 29.4 vs. 14.5 vs. 22.3 29.8 vs. 37/52.1/2.8 27.4 vs. 35.6 vs. 22.3 vs. 14.1 vs. 17.6 25.1 17.5
 ≥75 years 273 0.2:1 39.9. vs. 26.7 vs. 8.8 vs. 24.6 31.1 vs. 37.9/59.7/0.7 13.9 vs. 15.4 vs. 9.7 vs. 0.2 vs. 5.5 16.5 8
Vaccher et al. (2002)7 1975–1998 2143 OC vs. OPh vs. HPh vs. Lx I + II vs. III + IV/T3 + 4/N0/M1 Curative vs. palliative/S + RT vs. RT + ChT 5-Year OSc/CSSb
 <75 years 1962 10.3:1 28 vs. 19 vs. 13 vs. 39 vs. 39 vs. 16/41/54/2 71 vs. 21/29 vs. 10 44/59 n.r.
 ≥75 years 181 7.2:1 23 vs. 17 vs. 10 vs. 49 52 vs. 47/39/72/2 69 vs. 31 vs. 11 vs. 6 31/55 n.r.
Derks et al. (2005)8 1998–2001 266 OC vs. Ph vs. Lx II vs. III vs. IV Standard vs. w/o TH 5-Year OSb,d
 45–60 years 148 2.6:1 38 vs. 52 vs.10 18 vs. 20 vs. 63 89 vs. 4 38% n.r.
 ≥70 years 118 1.6:1 49 vs. 26 vs. 25 25 vs. 26 vs. 48 62 vs. 14 32% n.r.
Huang et al. (2011)9 2003–2007 2312 OC vs. OPh vs. HPh vs. Lx 0–II vs. III + IV/T3 + 4/N0 Curative vs. palliative vs. w/o TH 5-Year CSSc,e
 <75 years 1860 2.7:1 19 vs. 26 vs. 5 vs. 21 30 vs. 64/43/42 93 vs. 5 vs. 2 75.4 n.r.
 ≥75 years 452 1.8:1 25 vs. 15 vs. 7 vs. 30 35 vs. 57/47/56 79 vs. 10 vs. 11 64.9 n.r.

Ref., reference; N, number of patients; M, male; F, female; PT, primary tumor; OC, oral cavity; OPh, oropharynx; HPh, hypopharynx; Lx, larynx; S, surgery; OS, overall survival; ST, surgery for the primary; SN, surgery for the neck; RT, radiotherapy; ChT, chemotherapy; CSS, cause-specific survival; Ph, pharynx (oro- and hypo-); n.r., not reported; w/o TH, without therapy.

a

Estimated from the Fig. 2 in the Ref. 5.

b

P > 0.05.

c

P < 0.05.

d

Estimated from Ref. 32, Fig. 1.

e

For patients who received definitive radiotherapy (N = 1487).